Hematologic Oncology | Specialty

Concurrent Cladribine/Rituximab Enhances MRD-Free Complete Responses in Hairy Cell Leukemia

May 22nd 2020

Concurrent frontline therapy with cladribine and rituximab led to a significant improvement in minimal residual disease–free complete responses versus cladribine followed by delayed rituximab in patients with hairy cell leukemia.

Dr. Smith on Unmet Clinical Needs in Indolent Lymphomas

May 22nd 2020

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Belumosudil Impresses in cGVHD, FDA Submission Started

May 21st 2020

Belumosudil (KD025) continued to show high levels of clinical activity in patients with previously treated chronic graft-versus-host disease.

ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 21st 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Schroeder on the Importance of JAK Inhibition in GVHD

May 19th 2020

Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).

Scoring System Stratifies Risk of Heart Failure in Patients With Acute Leukemia

May 18th 2020

Baseline clinical characteristics coupled with measurable cardiac parameters can be used to predict the risk of heart failure among adults with acute leukemia who receive anthracycline-based therapy, according to recent study findings.

Ruxolitinib Demonstrates Early Efficacy in Chronic GVHD

May 15th 2020

Rushang D. Patel, MD, PhD, discusses the potential role of ruxolitinib in the treatment of patients with cGVHD.

Dr. Kansagra on Updates With CAR T-Cell Therapy in Hematologic Cancers

May 15th 2020

Ankit Kansagra, MD, discusses key updates with CAR T-cell therapy in hematologic cancers.

CLR 131 Mechanism of Action

May 15th 2020

Ruxolitinib Demonstrates Early Efficacy in Chronic GVHD

May 15th 2020

Rushang D. Patel, MD, PhD, discusses the potential role of ruxolitinib in the treatment of patients with cGVHD. 

Dr. Daver on Anticipated Breakthroughs in AML

May 15th 2020

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Brentuximab Vedotin Approved in Europe for Frontline ALCL

May 14th 2020

The European Commission has approved brentuximab vedotin for use in combination with chemotherapy for the frontline treatment of adult patients with systemic anaplastic large cell lymphoma.

SNDX-5613 Shows Early Promise in Acute Leukemias

May 14th 2020

Michael J. Thirman, MD, further discusses the novel compound, SNDX-5613, and sheds light on the next steps for this research.

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCL

May 14th 2020

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Community Advice: SQ Formulation of Daratumumab

May 13th 2020

Real-World Experience With SQ Monoclonal Antibodies

May 13th 2020

Study Overview: COLUMBA and PLEIADES

May 13th 2020

Infusion-Related Adverse Events

May 13th 2020

Medication Supplements Prior to IV Administration

May 13th 2020